DIFFERENT DOSAGE OF BEVACIZUMAB TREATMENT IN RECURRENT IDHWT GLIOBLASTOMA/IDHMUT GRADE 4 ASTROCYTOMA AND ITS IMPACT ON OUTCOME

A. Bosio,M. Caccese,M. Padovan,G. Cerretti,V Zagonel,G. Lombardi

Annals of Oncology（2022）

引用 0|浏览0

暂无评分

摘要

Angiogenesis is one of the most distinctive hallmarks of glioblastoma (GBM). The aim of this study is to assess the difference in terms of survival and safety between the 5mg/m2 and 10mg/m2 bevacizumab schedule in recurrent GBM.

查看译文

关键词

recurrent idhwt glioblastoma/idhmut,bevacizumab treatment,astrocytoma,different dosage

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要